Market Trends of Primary Biliary Cholangitis (PBC) Therapeutics Industry
This section covers the major market trends shaping the Primary Biliary Cholangitis Therapeutics Market according to our research experts:
Obeticholic Acid to Grow at Significant Rate
- Presently, there is no total cure for the disease. But, the liver damage can be delayed using the therapeutics. Ocaliva is a semisynthetic bile acid analogue which is used as a primary drug for the treatment of primary biliary cholangitis.
- On the other hand, Ursodeoxycholic acid is a secondary bile acid produced by intestinal bacteria. This shows advanced effects on kidney destruction, but a few percentages of the patient shows intolerance to the drug.
- According to the U.S. Department of Health and Human Services, 65 out of 100,000 women and about 10 of 100,000 men in the United States have primary biliary cholangitis.
- Moreover, factors such as the increase in R&D investments and presence of robust pipeline in for autoimmune diseases, especially primary biliary cholangitis are anticipated to boost the market growth over the forecast period.
North America to Have Significant Growth
Among the regional segments, North America is projected to have significant market growth owing to well-established healthcare infrastructure, presence of key market players and recent product launches. Moreover, the growing number of patients with the primary biliary cirrhosis and growing demand for the therapeutics is anticipated to fuel the market growth over the forecast period. Ocaliva drug was approved in 2016, in Europe and the United States, and had notable initial sales, however, the recent black box warnings from the regulatory authorities have impacted the usage. There is a tremendous need for the development of new therapeutics, and it is taken up by the market players in the region anticipated to boost the regional growth.
